GCC Presentation - Yokohama November 2004.ppt
Download as PPT, PDF0 likes16 views
The document discusses the Gulf Co-operative Council (GCC) and its health ministers' coordination, focusing on the Gulf Central Committee for Drug Registrations (GCC-DR) and its responsibilities such as pharmaceutical registration and quality control inspections. Established in 1976, the GCC-DR has achieved significant milestones including the registration of numerous pharmaceutical companies and products. Key operational features include regular meetings, anonymous decision-making, and adherence to group purchasing programs.
GCC Presentation - Yokohama November 2004.ppt
- 1. Where Do I Come from Where Do I Come from ? ?
- 2. GCC Central Registration GCC Central Registration Ibrahim A. Alshowaier PhD Vice President Saudi Food and Drug Authority (SFDA)
- 3. The Gulf Co-operative Council (GCC) The Gulf Co-operative Council (GCC) Saudi Arabia, Kuwait, Oman United Arab Emirates, Bahrain Qatar and Yemen. Total population estimated at 45 million inhabitants. The GCC is a co-operation organ in different domains including health. The various councils of ministers of the participating countries meet twice a year to discuss existing and new co- operation issues. 2
- 4. The Gulf Co-operative Council For Health Ministers The Gulf Co-operative Council For Health Ministers Coordinating and ensuring communication with and between the Ministers of Health of member countries. Organizing conferences, seminars, and training courses. Conducting field surveys and researches for common interest of Gulf States. Procurement of safe and efficient pharmaceutical products, hospital sundries and equipments of high quality. Assessment of the existing systems and strategies in the health fields. 3
- 5. The Executive Office The Executive Office Established in 1976. Executive board chaired by the executive director. Health ministers’ council. Advisory committees. Functions: 4 Group purchasing. Central drug registration. Health policies. Medical research.
- 6. Gulf Central Committee for Drug Registrations (GCC DR) Gulf Central Committee for Drug Registrations (GCC DR) . . (GCC-DR). approved in may 1999. Located in the Executive Office for Health Ministers, Riyadh, Saudi Arabia. Two members nominated by each state. Two consultants appointed by Executive Director. Committee chairman nominated for one year. 5
- 7. GCC - DR GCC - DR Meeting can be held with minimum of 4 states. Decision must be anonymous. Minimum 4 meetings per year. Committee decisions are bound to SGH group purchasing program. Full time secretary. Committee decisions can petitioned to executive director. 6
- 8. GCC GCC – – DR Responsibilities DR Responsibilities Registration of pharmaceutical companies. Registration of pharmaceutical products. Inspection of pharmaceutical companies for GMP compliance. Approval of Quality Control Laboratories (QCL). Reviewing of Technical and PMS reports. 7
- 9. 8
- 10. 9
- 11. 10
- 12. 11
- 13. 12
- 14. 13
- 15. 14
- 16. 15 GCC-DR Achievements GCC-DR Achievements 20 20 Meeting to date. Registration of 96 96 pharmaceutical companies. Registration of 533 533 products. Preparation of technical guidelines for: GMP standard. Bioequivalence guidelines. Stability guidelines. GLP guidelines. PMS guidelines.
- 17. The most Frequently asked questions The most Frequently asked questions • Submission of new product File centrally or nationally. • Re-Registration of products registered in some & not all other Gulf markets. • Legalization? Embassies. • Co-Marketing, Co-manufacturing. • CPP/which country. 16
- 18. • Authenticated from the relevant authorities. Certificate of analysis. Package insert. Animal source. Site change. • Old products which already registered in all state. 17
- 19. GCC Update 56 Conference – Doha, 5 – 6 January 2004 The committee should start the pricing of the new products registered centrally from the beginning of 2004 and CIF price in single international currency. 18 Resolution No. 11-Z Resolution No. 11-Z
- 20. GCC Update Executive Board Meeting Executive Board Meeting 60th meeting of 60th meeting of Riyadh – 12 – 14 April 2004 Riyadh – 12 – 14 April 2004 Recommendation: Recommendation: The members were asked not to register the company which produce generic products until it is registered centrally. 19
- 21. Pharmaceutical SGH Tenders: Bids presented for (sensitive) drugs with uncontrollable effectiveness, must be centrally registered; e.g: 20 a. Generic drugs for which bioequivalence studies cannot be done, e.g. inhalable medicines and some nasal inhalers. b. Drugs supported by biotechnology for which bioequivalence studies cannot be done and which require clinical or pharmacodynamic studies. c. Drugs with narrow therapeutic spectrum, which are administered orally.
- 22. The registered items to participate with in the SGH tenders are those which are provided by the member GCC countries having reference laboratories or being centrally registered. However, the Executive Board Office should receive the lists including such items, one month prior to opening envelopes date. 21 Pharmaceutical SGH Tenders: